Update On Antibody-Drug Conjugates (ADCs) For MBC - Metastatic Breast Cancer Trial Talk

Research News

Antibody-drug conjugates consist of an antibody attached to a chemotherapy drug that delivers chemotherapy only where it is needed, limiting unwanted side effects. ADCs work by combining the ability of antibodies to target cancer cells with the ability of chemotherapy drugs to kill cancer cells.

Three ADCs are approved for MBC: ado-trastuzumab emtansine (Kadcyla®) for HER2+ MBC, fam-trastuzumab deruxtecan (Enhertu®) for HER2+ MBC, and sacituzumab govitecan-hziy (Trodelvy®) for triple-negative MBC. Others are being tested in clinical trials.

Read below for general information about how ADCs work, a recent comparison of the two ADCs for HER2+ MBC, and news about sacituzumab govitecan-hziy (Trodelvy®), the recently approved ADC for triple-negative MBC.

General Information About ADCs
ADCs For HER2+ MBC
ADC For Triple-Negative MBC
Clinical Trials That Include Antibody-Drug Conjugates

Last Modified on March 10, 2022

Tags:

SEARCH OUR SITE

for past articles or specific information.